Research programme: anticancer fleximer antibody-drug conjugates - Asana BioSciencesAlternative Names: ASN 004; Dolaflexin® ADC - Asana BioSciences; Fleximer® - ADC - Endo Pharmaceuticals/Mersana Therapeutics
Latest Information Update: 26 May 2015
At a glance
- Originator Endo Pharmaceuticals
- Developer Asana BioSciences
- Class Antineoplastics; Depsipeptides; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Mitosis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer